About Onyx
Onyx is a company based in San Francisco (United States) founded in 1992 was acquired by Legacy Acquisition in September 2020. Onyx operates in a competitive market with competitors including Jazz Pharmaceuticals, C4 Therapeutics, Erasca, Revolution Medicines and MiRagen, among others.
- Headquarter San Francisco, United States
- Stage Public
- SectorsHealthcare
- Website onyx.com
- Social LinkedIn
- Acquired by Legacy Acquisition (Sep 2020)
- Latest Funding Round$10M (USD), Post-IPO
Feb 2003
- InvestorsAmgen
& 1 more
- Acquired by
Funding Insights of Onyx
- Total Rounds 3
- Last Round Post-IPO — $10M
- First Round $18M
(Jan 2000)
All 3 funding rounds of Onyx with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb 2003 | $10M | Post-IPO | – | – | – |
| Jun 2002 | $20.07M | Post-IPO | – | – | – |
| Jan 2000 | $18M | Post-IPO | – | – | – |
2 investors in total: 2 institutional.
Investors in Onyx
Onyx has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include Amgen and Legacy Acquisition.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Developer of pharmaceutical products for treating multiple diseases | 1980 | amgen.com | Thousand Oaks, United States | |
Offers comprehensive fund management solutions to clients. | 2017 | legacyacquisition.com | Cincinnati, United States |
Investor details for Onyx
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Onyx
6 dated milestones of Onyx across 28 years, from founding to its latest funding, stage changes and deals.
- Founded Onyx is founded.
- IPO Lists on the stock exchange (IPO).
- Funding First funding round of $18.0M.
- Funding Latest funding round, Post-IPO, of $10.0M.
- Exit Acquired by Amgen.
- Exit Acquired by Legacy Acquisition.
Competitors of Onyx
Onyx operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, C4 Therapeutics, Erasca, Revolution Medicines and MiRagen, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| jazzpharma.com | 2003 | Dublin, Ireland | $265M | 2,800 | Novel biopharmaceutical medicines are developed for unmet medical needs. | |
| c4therapeutics.com | 2016 | Cambridge, United States | $223M | 121 | Small-molecule drugs for cancer treatment are developed via Degronimid platform. | |
| erasca.com | 2018 | San Diego, United States | $300M | 120 | Small molecule therapeutics for cancer treatment are developed. | |
| revmed.com | 2014 | Redwood, United States | $326.29M | 181 | Cancer therapies are developed using selective pathway inhibitors. | |
| miragen.com | 2007 | Boulder, United States | $111.29M | 92 | MicroRNA-based therapeutics are developed for treating multiple diseases. | |
| mereobiopharma.com | 2015 | London, United Kingdom | $119M | 56 | Therapeutics for cancer and rare diseases are developed. | |
| nimbustx.com | 2009 | Cambridge, United States | $685M | 81 | Targeted therapeutics for cancer, metabolic, and inflammatory diseases are developed. |
Detailed competitors of Onyx
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Onyx
The website of Onyx (onyx.com) receives about 3.6K visits a month.
- Monthly visits3.6K
▼ 32.7% vs previous month
Websites whose visitors overlap most with Onyx. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| oracle.com | 100% | 18.1M | #2,347 | View details | |
| talisma.com | 91% | 28.6K | #1,338,740 | View details | |
go.infor.com | go.infor.com | 90% | – | – | – |
| chordiant.com | 88% | – | – | View details | |
onyxmac.com | onyxmac.com | 88% | – | #10,337,657 | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 15 similar websites and full traffic analytics for Onyx
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 15 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Latest news on Onyx
Complete news archive for Onyx
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Onyx
10 companies that operate in the same segment as Onyx (Oncology), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Novel biopharmaceutical medicines are developed for unmet medical needs. | 2003 | Dublin, Ireland | USD 265 M | USD 4.27 B | 2,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 2,020 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 3.22 B | USD 147.17 M | 1,000 | |
Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed. | 2002 | Saint-genis-pouilly, Ain, France | USD 56.13 M | USD 235.08 M | – | |
Developer of small molecule drugs for the treatment of cancer and inflammatory disease | 2008 | Natick, Massachusetts, United States | USD 98.4 M | USD 146.07 M | 279 | |
Small molecule therapeutics are developed for cancer and rare diseases. | 2017 | New York, New York, United States | USD 229.6 M | – | – | |
Small-molecule drugs for cancer treatment are developed via Degronimid platform. | 2016 | Cambridge, Massachusetts, United States | USD 223 M | USD 35.95 M | 110 | |
Developer of drugs based on T-Cell receptor technology for the treatment of cancer | 2008 | Abingdon, Oxfordshire, United Kingdom | USD 601.28 M | USD 400.95 M | 493 | |
Antibody-based drugs are developed for autoimmune diseases and cancer treatment. | 2008 | Ghent, East Flanders, Belgium | USD 61.9 M | USD 1.41 B | 355 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Onyx
Onyx was founded in 1992 and raised its 1st funding round 8 years after it was founded.
Onyx is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Onyx Pharmaceuticals was founded in 1992 in San Francisco, United States, within the biotechnology sector. Medicines targeting various cancers are developed and commercialized by the company. The portfolio features Sorafenib, used for advanced renal cell carcinoma; Carfilzomib, applied in multiple myeloma cases; and Regorafenib, indicated for metastatic colorectal cancer. Operations focus on oncology therapeutics in the U.S. market.
Onyx's top competitors include Jazz Pharmaceuticals, C4 Therapeutics and Erasca.
Onyx has 2 investors. Key investors include Amgen, and Legacy Acquisition.
Yes. Onyx was acquired by Legacy Acquisition in September 2020.